Morningstar

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
Nasdaq

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Medical Xpress

Molecular test helps tailor chemotherapy for advanced prostate cancer patients

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...
Business Wire

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...
Medscape

Predictive Biomarker Guides Prostate Cancer Hormone Therapy

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...